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Review
Copper (Cu) is an essential trace element (TE) required for 
metabolism in all living cells. It has been known to be an essen-
tial component of parenteral nutrition (PN) since 1972.1 Provision 
of the correct amount of Cu is necessary, not only to avoid defi-
ciency and toxicity, but also to promote optimal recovery.2 This 
article covers the relevant physiology of Cu. It then discusses Cu 
deficiency and toxicity and examines the evidence behind the 
recommendations on Cu provision in PN. It provides practical 
guidance on assessment of Cu status and Cu requirements. The 
article focuses on adults because provision of Cu in pediatric PN 
has recently been covered elsewhere,3 but pediatric studies have 
been cited where considered appropriate.
Physiology
Cu is among the 3 most abundant transition metals in biologi-
cal systems, the other 2 being iron (Fe) and zinc (Zn). The 
human body contains around 100 mg of Cu, more than half of 
which is in bone and muscle. The highest concentrations are in 
liver, kidney, and brain, reflecting the high metabolic activity 
of these organs.2 Only 5% is in blood, about 95% of this being 
bound to ceruloplasmin (Cp) and the remainder to albumin and 
amino acids.4 The serum Cu concentration therefore largely 
reflects the Cp concentration and is affected by factors influ-
encing Cp. Intracellular Cu is usually bound to chaperones and 
other proteins because free Cu is potentially harmful to cells.
Cu, which functions as a component of cuproproteins, has a 
variety of physiologic roles. For example, it is required for 
humoral immunity and production of inflammatory cytokines.5,6 
It was recently suggested that the immune system uses Cu intox-
ication as a means of intracellular bacterial killing.7,8 Cu is 
required for the physiologic response to low Fe stores. It is 
needed for absorption of dietary Fe, release of Fe from hepato-
cytes and production of hemoglobin.9 Cp oxidizes Fe from the 
ferrous to ferric state, enabling its transport by transferrin and 
subsequent use in erythropoiesis. Superoxide dismutase is an 
antioxidant cuproenzyme that catalyzes the conversion of super-
oxide radicals to hydrogen peroxide, which is then reduced to 
water.10 Cu is also necessary for wound healing because it is 
required for the synthesis of collagen.
The average daily oral intake of Cu is 1.0–1.6 mg, which 
exceeds the RDA of 0.9 mg.11 Dietary Cu is absorbed mainly in 
the stomach and upper small intestine.2,12 About 55%–75% of 
dietary Cu is absorbed, which is a high proportion as compared 
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with other TEs.2 The amount of Cu absorbed depends on 
dietary intake, Cu status, and the effects of other nutrients. 
Absorption is decreased by vitamin C, Fe, and Zn.2 Zn inhibits 
Cu transport directly and by inducing metallothioneins that 
bind Cu in intestinal mucosal cells. Short-chain fructo-oligo-
saccharides13 and Fe deficiency9 increase Cu absorption. Once 
absorbed, Cu is bound to albumin and transcuprein and trans-
ported to the liver, where it is stored, released into the systemic 
circulation, or excreted into bile. Normally, about 80% of Cu 
excreted from the body is in bile and gastrointestinal (GI) 
secretions, and about 20% is in urine.14,15 About 10%–15% of 
biliary Cu is reabsorbed, returning to the liver in an enterohe-
patic circulation. External fluid losses from fistulae, bile leaks, 
or enterostomies predispose to Cu deficiency by decreasing the 
amount of Cu reabsorbed.
Cu Deficiency
Deficiency occurs when Cu intake is consistently below 
requirements. This section focuses on Cu deficiency encoun-
tered among patients receiving nutrition support. Factors 
affecting individual susceptibility to deficiency during PN 
include the size of hepatic Cu stores, the extent of GI losses, 
and the amount of Cu provided. Cu provision includes supple-
mentation of PN but also the amount delivered by concurrent 
oral or enteral nutrition and as a contaminant of PN and other 
intravenous (IV) fluids.
Causes of Cu Deficiency
Overt Cu deficiency is uncommon during short-term PN but 
has occurred during long-term PN when Cu has been provided 
below requirements.16-19 A recent retrospective review of the Cu 
status of hospitalized pediatric patients treated with PN 
observed that, after 14 days of treatment, hypocupremia was 
present in 71% of patients receiving PN unsupplemented with 
Cu, as compared with 50% of those receiving supplemented 
PN.20 Deficiency has also occurred when supplemental Cu has 
been withheld either because of concern about accumulation 
during cholestasis21,22 or because of shortages of multi-TE 
(MTE) products.23-25 There is much concern about the clinical 
implications of such shortages, especially for infants, for whom 
micronutrient deficiency can have irreversible consequences.26 
The prevalence of marginal Cu deficiency among patients 
treated with PN is unknown but could be anticipated to be 
higher than that in the general population, given the higher 
prevalence of risk factors for deficiency in hospitalized patients.
Short bowel syndrome. Patients with short bowel syndrome 
(SBS) are at risk of Cu deficiency even after weaning onto oral 
diet. A recent study investigated 22 adults with SBS following 
intestinal resection, of whom half had been weaned onto oral 
diet and half remained dependent on PN.27 Patients in the PN 
group had a small intestine with a median length of 25 cm 
(range, 10–100), and 6 patients had a colon. Patients in the 
orally fed group had a small intestine with a median length of 
110 cm (range, 40–210), and 9 patients had a colon. Serum Cu 
concentrations were significantly lower for the patients treated 
with PN (69 ± 24 µg/L, P < .05) and patients taking oral diet 
(72 ± 26 µg/L, P < .05), as compared with a control group (109 
± 16 µg/L; reference range, 70–140 µg/L). Similarly, Cu defi-
ciency can occur during transition from PN to enteral nutrition 
(EN). A study of transition to EN for pediatric patients reported 
Cu deficiency as the most common among micronutrients, 
affecting 56% of patients.28 After full EN was established, defi-
ciency of Cu was less prevalent (22%) than vitamin D (68%), 
Zn (67%), or Fe (32%). These findings emphasize the impor-
tance of monitoring Cu status among patients with SBS, irre-
spective of the type of nutrition support.
Teduglutide—an analogue of glucagon-like peptide 2, 
which is an intestinal growth factor—has been used in patients 
with SBS to improve absorption of dietary nutrients and 
decrease dependence on PN. A recent case series reported on 
adverse events during weaning of patients treated with tedu-
glutide.29 One patient developed overt Cu deficiency, despite 
Cu supplementation, which did not respond to oral supplemen-
tation and necessitated recommencement of PN. In this patient, 
it appears that Cu absorption did not improve in response to 
teduglutide. Glucagon-like peptide 2 has recently been 
observed to improve bile flow in an animal model of cholesta-
sis,30 but its effect on Cu balance in humans is unknown.
Enteral tube feeding. Patients receiving long-term EN, espe-
cially those fed through a jejunostomy tube, are at risk of 
developing Cu deficiency. For example, one case series com-
pared 23 patients fed through percutaneous endoscopic jeju-
nostomy and 36 patients fed via percutaneous endoscopic 
gastrostomy.31 After 6 months of EN, serum Cu was signifi-
cantly lower in the percutaneous endoscopic jejunostomy 
group (P < .001). Six patients in this group had severe Cu defi-
ciency with hematologic features. There have also been reports 
of severe Cu deficiency in patients on home EN via percutane-
ous endoscopic gastrostomy.32 Enterally fed patients appear to 
be at risk of Cu deficiency because of decreased bioavailability 
rather than inadequate intake. The risk is higher in jejunos-
tomy-fed patients because the main sites of Cu absorption are 
bypassed. In addition, interindividual variation in Cu absorp-
tion is high. Furthermore, absorption may be impaired by high 
enteral intake of Zn or Fe.
Bariatric surgery. Cu deficiency can occur after bariatric sur-
gery, more commonly after biliopancreatic diversion than after 
Roux-en-Y gastric bypass. A 5-year follow-up study observed 
hypocupremia postoperatively in 30.3% of patients with bilio-
pancreatic diversion, compared with 3.8% of patients with 
Roux-en-Y gastric bypass.33 None of the patients had hemato-
logic or neurologic features of deficiency, which suggests that, 
for overt deficiency to occur, deficiency must be sustained 
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long-term. Cu deficiency after bariatric surgery has recently 
been reviewed.34,35 Clinical Cu deficiency has been described 
but is unusual for patients receiving adequate supplementation. 
The American Association of Clinical Endocrinologists’ guide-
lines for perioperative support of the patient undergoing bariat-
ric surgery recommend that Cu does not need to be routinely 
measured postoperatively but should be measured if there are 
hematologic or neurologic features consistent with deficiency 
or if there is impaired wound healing.36 Clinicians should mon-
itor patients carefully for these features.
Zn excess. Zn-induced Cu deficiency (ZICD) has been 
caused by excessive ingestion of Zn, but there is limited 
awareness among clinicians of this potential side effect of Zn 
supplementation.37 It tends to occur with oral Zn doses >850 
mg/d for 1 year, but negative Cu balance has resulted from 
doses of 18.5 mg/d for 2 weeks.38 Misdiagnosis of Zn defi-
ciency during an acute phase response (APR) can result in 
inappropriate Zn supplementation. ZICD should therefore be 
considered for patients treated with PN, many of whom have 
an ongoing APR and high Zn requirements. For patients 
treated with PN, the source of excess Zn may not necessarily 
be parenteral. For example, excessive intake of Zn from a 
denture adhesive was recently reported to cause ZICD for a 
patient on long-term PN containing standard Cu provision.39 
The patient presented with mild pancytopenia and perioral 
paraesthesia, which did not respond to additional Cu provi-
sion but resolved after the adhesive was switched to a Zn-
free product. To facilitate diagnosis of ZICD, it has been 
recommended that, following the finding of hypocupremia, 
TE laboratories should automatically measure the Zn of the 
specimen.40 Similarly, the finding of hyperzincemia should 
prompt the measurement of Cu to exclude ZICD. To avoid 
ZICD, it has been suggested that, to treat Zn deficiency, 1 mg 
of Cu should be given for every 8–15 mg of Zn (elemental 
doses).36 Zn and Cu should be taken at least 2 hours apart to 
maximize the absorption of Cu.41
Other causes of Cu deficiency. Cutaneous exudative Cu losses 
amounting to 37 mg/wk have been reported for patients with 
severe burns.42 There is evidence that supplementation of Cu in 
combination with other micronutrients improves the clinical 
outcome for patients with burns43 or pressure ulcers.44 The 
results of 2 randomized controlled trials were combined in 
which patients with burns received placebo or a combination 
of Cu, selenium, and Zn at doses up to 4 mg, 500 µg, and 40 
mg, respectively, by IV infusions not associated with PN use.45 
In total, 41 patients were investigated for up to 21 days. There 
was a significant reduction in nosocomial pneumonia in 
patients supplemented with TE. The extent to which this out-
come was attributable to Cu is unknown.
As with other micronutrients, Cu is readily dialyzed. 
Continuous renal replacement therapy can result in significant 
Cu losses, especially if prolonged. If Cu provision is insufficient 
to replace losses, this will lead to negative Cu balance. Effluent 
losses of 0.41 mg/d have been reported,46 an amount similar to 
the recommended Cu provision in PN. In the same study, Cu was 
undetectable in replacement solutions. Hemodialysis and perito-
neal dialysis have not been associated with Cu deficiency in 
human subjects, but a recent study in an animal model concluded 
that hemofiltration may necessitate Cu replacement at doses 
exceeding standard provision.47
Chemotherapy with cisplatin should be considered a risk 
factor for Cu deficiency. Patients with esophageal cancer 
treated with cisplatin and PN had significantly lower serum Cu 
concentrations postchemotherapy (P = .015).48 This change 
was prevented by additional TE supplementation. Iatrogenic 
Cu deficiency has also been observed following overtreatment 
with chelating agents, such as penicillamine, trientine, and tet-
rathiomolybdate, but this has not been reported in the context 
of PN.49
Features of Cu Deficiency
When intake is below requirements, Cu is initially replenished 
from hepatic stores. As a result, features of deficiency may 
occur long after the causal insult. When deficiency has occurred 
after omission of Cu from PN, clinical features have taken 
between 6 weeks and 15 months to appear.21-23,25,50,51 In a series 
of 26 cases of neurologic complications occurring after bariat-
ric surgery, overt Cu deficiency presented as late as 9 years 
postoperatively.52
The clinical features of Cu deficiency are mainly hemato-
logic and neurologic, reflecting the requirement for Cu in 
erythropoiesis and synthesis of myelin.53 The most common 
features are a microcytic or normocytic anemia, unresponsive 
to Fe supplementation, and neutropenia.54 The mechanism 
whereby anemia develops is uncertain, but decreased Cp may 
result in impaired mobilization of Fe stores. Cu deficiency is 
also implicated in increased oxidative stress and deterioration 
in cognitive function for patients with Alzheimer’s disease.55
The most common neurologic feature of Cu deficiency is 
myelopathy, but peripheral neuropathy and demyelination have 
also been reported.56 The deficits of myelopathy resemble those 
of subacute combined degeneration of the cord resulting from 
vitamin B
12
 deficiency.57 Patients typically present with a disor-
dered gait and sensory ataxia. The mechanism of neurologic 
damage is unknown, but cuproenzymes such as cytochrome C 
oxidase have vital roles in the nervous system, the impairment 
of which would be expected to have adverse effects. When neu-
rologic features consistent with Cu deficiency are present, the 
patient should be investigated by measurement of serum Cu and 
by spinal magnetic resonance imaging. In a case series of 25 
patients with Cu deficiency myelopathy, abnormalities on mag-
netic resonance imaging were found in 44%, the most common 
being an increased T2 signal of the dorsal column in the cervi-
cal and thoracic cord.58 In this case series, the duration of 
patients’ symptoms prior to diagnosis of Cu deficiency ranged 
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from 2 months to 10 years. Treatment with Cu supplementation 
may arrest the neurologic deficits and result in improvement in 
sensory symptoms, but most patients have residual deficits 
resulting from irreversible neurologic injury. This emphasizes 
the importance of early diagnosis. Several months of Cu sup-
plementation are likely to be required before the features 
improve. A study of 12 patients with Cu deficiency, all of whom 
had neurologic features, observed significant improvements in 
functional activities of daily living (P = .007) over 12 months of 
Cu supplementation.59
Nephrotic syndrome was recently reported as a feature of 
Cu deficiency for a patient treated with PN following bowel 
resection.60 The patient also had anemia, neutropenia, and 
deteriorating kidney function, which responded to Cu supple-
mentation. The urinary protein loss was attributed to loss of 
the protective effect of Cp on glomeruli. While this is the 
only published case report of nephrotic syndrome resulting 
from Cu deficiency, urinary protein loss has been reported to 
correlate with urine Cu for patients with nephrotic 
syndrome.61
Cu deficiency should be considered when metabolic bone 
disease occurs for patients treated with PN. The earliest 
reported case of Cu deficiency for a patient treated with PN 
was an infant who presented with osteoporosis and growth 
delay.1 Osteoporosis resulting from Cu deficiency was also 
reported in 2 preterm infants with SBS treated with long-term 
PN.62 It was diagnosed at 5 months of age following investiga-
tion for musculoskeletal discomfort. Both patients had severe 
hypocupremia and responded to IV supplementation of Cu. 
Pseudoscurvy has been reported as a feature of Cu deficiency,63 
as demonstrated in a 4-month-old female infant treated with 
PN from which TEs had been omitted.
There is evidence from numerous sources that Cu defi-
ciency impairs the activity of the immune system, thereby 
predisposing to bacterial infection.5,64 In vitro studies have 
observed decreased neutrophil function, decreased secretion 
of interleukin 2 from lymphocytes, and decreased cytotoxic 
activity of natural killer cells. Mortality from infection is 
higher in Cu-deficient animals.65 For humans, it has long 
been known that Cu deficiency impairs phagocytosis66 and 
increases mortality from infection.67 Pulmonary and urinary 
tract infections are more common for patients with Menkes’s 
disease, an inherited disorder of severe Cu deficiency.68 The 
results of supplementation studies for patients with burns, 
discussed above, also suggest that Cu deficiency predisposes 
to pneumonia.45 The conclusions that can be drawn from clin-
ical studies regarding the role of Cu deficiency in infection 
are limited, given that micronutrient deficiencies do not occur 
in isolation; but, when taken together, the evidence is com-
pelling to suggest that Cu deficiency impairs the immune 
system.
The clinical consequences of marginal Cu deficiency are 
unknown but may include neurologic,57 cardiac,69 and immune 
dysfunction.5,70 A low-Cu diet has resulted in decreased 
proliferation of mononuclear cells.71 Given the extensive role 
of Cu in Fe metabolism, it could be anticipated that marginal 
Cu deficiency may compromise utilization of Fe. These obser-
vations suggest that marginal Cu deficiency could be detrimen-
tal for patients treated with PN, but this awaits investigation.
Treatment of Cu Deficiency
The underlying cause of deficiency should be sought and 
treated. For patients already supplemented with Cu, the dose 
should be reviewed and possible factors decreasing bioavail-
ability considered. Ideally, supplementation should be deliv-
ered orally or enterally, to enable absorption according to 
requirements and to avoid bypassing homeostatic mecha-
nisms. However, for patients treated with PN, enteral toler-
ance or bioavailability of Cu may be limited by intestinal 
failure. In addition, the need to ensure delivery of Cu for 
patients with severe deficiency may necessitate IV adminis-
tration. Supplementation should continue until normal serum 
Cu concentrations are restored and clinical features resolve. 
This should be followed by long-term supplementation suffi-
cient to prevent recurrence of deficiency. When Cu deficiency 
has occurred for patients treated with PN, serum Cu concen-
trations have normalized, and clinical features have improved 
within 6 weeks of supplementation.21,22,72 The hematologic 
features resolve within about 4 weeks, but neurologic features 
improve relatively slowly and may be in part irreversible. The 
rate of resolution of Cu deficiency is likely to depend on the 
severity of deficiency, route of supplementation, and Cu dos-
age. If features of deficiency do not respond to increased Cu 
provision, ZICD should be ruled out.
Cu dosing should be individualized according to the sever-
ity of hypocupremia and clinical features. Cu is available as 
MTE products, which typically provide 0.4–1.0 mg/mL, oral 
tablets (2 and 5 mg), and injection (0.4–2 mg/mL).73 Severe 
Cu deficiency in adults can be treated with IV Cu (2–4 mg/d) 
for 6 days, followed by oral Cu sulfate or gluconate (3–8 
mg/d).36 In a reported case of severe Cu deficiency, it was 
possible, following IV Cu supplementation, to maintain the 
serum Cu concentration in the reference range by high-dose 
oral supplementation (8 mg/d), despite loss of absorptive sur-
face area.74 This suggests that sufficient absorption may be 
achieved by supersaturation of the remaining Cu transport 
capacity.75
When Cu deficiency occurs during EN, there are various 
treatment options. Enteral Cu provision can be increased by 
giving either pharmaceutic Cu products or cocoa powder, of 
which 100 g contains 3.61–3.79 mg of Cu.76 In practice, daily 
doses of 10–40 g of cocoa powder have been used31 that, in this 
study, were reported to deliver Cu doses of 1.36–2.56 mg/d. 
Clinicians should be aware that Cu may be poorly absorbed 
when given through a jejunostomy tube.77 If necessary, IV Cu 
can be given. It is advisable to monitor Cu status for patients on 
long-term EN.
 by guest on October 21, 2016ncp.sagepub.comDownloaded from 
Livingstone 5
Cu Toxicity
Patients with acute Cu toxicity present with vomiting, diarrhea, 
and abdominal pain and, if more severe, hepatic necrosis, renal 
failure, encephalopathy, and death.78 Acute toxicity has been 
reported following consumption of Cu-contaminated water but 
would be unlikely to occur during PN, unless an error resulted 
in overdose. For patients treated with long-term PN, there is 
concern about hepatotoxicity resulting from chronic hepatic 
accumulation of Cu in PN-associated liver disease (PNALD). 
Accumulation may occur if biliary excretion of Cu is impaired, 
either because of immaturity of excretory mechanisms or 
because of cholestasis. Overload may be exacerbated by exces-
sive provision of Cu resulting from inappropriately formulated 
MTE products, contamination of PN, or additional intake from 
other sources.
There is extensive evidence that hepatic Cu accumulation 
occurs in PNALD. This is usually at concentrations below the 
diagnostic threshold for Wilson disease (WD)—that is, <250 
µg/g, dry weight (reference range, <35 µg/g).79,80 In 2005, 
Blaszyk et al measured hepatic Cu concentrations for patients 
treated with long-term PN who had abnormal liver enzymes 
and for control subjects who had drug-induced cholestasis.81 In 
89% of PN patients, hepatic Cu was >35 µg/g and in 29%, 
>250 µg/g (range, 10–2248). Hepatic Cu was also increased in 
the control subjects. It did not correlate with the serum Cu con-
centration or duration of PN. These findings suggest that cho-
lestasis is the main causal factor in hepatic Cu accumulation 
for patients treated with PN, but they do not exclude the pos-
sibility that excessive provision is harmful. Given that about 
30% of adult patients receiving long-term PN develop PNALD, 
the results from this small study, if typical of the PN popula-
tion, suggest that about 10% of adults on long-term PN have 
significant hepatic Cu accumulation. An autopsy study of tis-
sue TE concentrations was carried out in 8 adults with short 
bowel treated with long-term PN, compared with 45 control 
subjects on oral diet who had not suffered from GI disease.82 
Cu dosing was in accordance with 1979 recommendations,83 
the mean daily dose being 1.4 mg for 14 years. Cu concentra-
tions were increased in liver and kidney specimens from 
patients receiving PN, being highest (>250 µg/g) in 2 who died 
of liver failure.
While the clinical outcome in PNALD appears to be poor 
for patients with severe hepatic Cu accumulation, it is unclear 
whether the Cu is directly hepatotoxic. Various observations 
suggest that Cu accumulation may be harmful. Supraphysiologic 
concentrations of Cu are known to be pro-oxidant, generating 
reactive oxygen species that can cause oxidative damage to 
macromolecules.78 In addition, Cu accumulation in WD is hep-
atotoxic, neurotoxic, and nephrotoxic.79,84 However, PNALD 
and WD are not directly comparable, because they have differ-
ent causes and clinical features and the extent to which Cu 
causes harmful oxidative effects in vivo in PNALD is unknown, 
as are its macromolecular targets.85 Moreover, the observation 
that neonates tolerate high hepatic Cu concentrations without 
adverse effects suggests that Cu accumulation per se is not nec-
essarily harmful.86 Whether Cu is hepatotoxic may depend on 
factors other than its total hepatic concentration, including its 
subcellular location and extent of protein binding. It has also 
been suggested that Zn decreases the hepatotoxicity of Cu in 
WD,87 but whether it does so in PNALD is unknown. Until the 
results of further research clarify whether Cu is hepatotoxic in 
PNALD, Cu should be considered potentially harmful for 
patients treated with long-term PN. Chronic Cu toxicity is also 
implicated in atherosclerosis and neurodegenerative diseases, 
including Alzheimer’s disease and Parkinson’s disease.88
Assessment of Cu Status
Serum Cu
All currently available biomarkers of Cu status are unreliable. 
The serum Cu concentration is the most useful and most fre-
quently ordered test, but its limitations need to be considered.89 
When interpreting individual results, the clinician should first 
consider how reliably this can be done through the population 
reference range. Second, when interpreting serial results, the 
clinician must decide whether a change between consecutive 
results is significant, possibly requiring clinical intervention, 
or can be accounted for by a combination of biological varia-
tion and analytic imprecision. Regarding use of the reference 
range, serum Cu has an index of individuality of 0.41, which is 
low (ie, a ratio of intraindividual variation to interindividual 
variation).90 Consequently, results within the reference range 
do not exclude the possibility that there has been a disease-
related change in concentration that is highly significant for the 
individual. Unless a previous result is available for compari-
son, the clinician will be unaware of the significance of the 
result. Clearly, this low index of individuality decreases the 
value of the population reference range for interpreting indi-
vidual serum Cu results. Regarding serial results, critical dif-
ference values can help clinicians interpret the significance of 
changes. Serum Cu has been reported to have a critical differ-
ence of 2.3 µmol/L (14.6 µg/L), suggesting that a relatively 
small change between consecutive results is likely to be sig-
nificant.90 Critical differences should ideally be determined by 
all clinical laboratories because the values are influenced by 
analytic imprecision, which varies among laboratories.91
The serum Cu concentration is insensitive to deficiency, 
tending to remain within the reference range except in severe 
deficiency. A normal or increased serum Cu result does not 
therefore rule out deficiency.15 It is also insensitive to hepatic 
Cu accumulation, tending to plateau once requirements are met 
and correlating poorly with tissue accumulation.14,81,82 The 
lack of correlation with Cu status makes serum Cu an unreli-
able test for guiding supplementation of PN, except at 
extremes.92 Hypocupremia can occasionally occur in the 
absence of deficiency (eg, for patients with WD).93 When the 
 by guest on October 21, 2016ncp.sagepub.comDownloaded from 
6 Nutrition in Clinical Practice XX(X)
cause of hypocupremia is uncertain, WD can be ruled out by 
the finding of a 24-hour urinary Cu ≤0.6 µmol.94
Confounding factors cause serum Cu to increase in the 
absence of Cu excess, the most common being the APR, during 
which proinflammatory cytokines stimulate the synthesis of 
Cp irrespective of Cu status. Indeed, hypercupremia is to be 
expected in hospitalized patients with trauma or infection or in 
those who are postsurgical.95 A recent retrospective review of 
Cu status in hospitalized patients treated with PN observed that 
serum Cu correlated with C-reactive protein concentrations >4 
mg/dL (P = .03).20 This APR-associated increase in serum Cu 
concentrations can mask deficiency2 or cause unnecessary con-
cern about toxicity, either of which could result in inappropri-
ate clinical action. In addition, serum Cu concentrations 
measured for monitoring the treatment of deficiency should be 
interpreted with caution if there is a concurrent APR. Cp syn-
thesis is also stimulated by estrogens, resulting in increased 
serum Cu concentrations among women who are pregnant or 
taking estrogens. In the presence of these confounding factors, 
serum Cu concentrations within the reference range do not 
exclude deficiency, but hypocupremia is consistent with a 
diagnosis of Cu deficiency.14,15,96,97
It is advantageous to measure the Cp concentration when 
measuring serum Cu. Both increase in parallel because their 
concentrations are approximately linearly related. Any increase 
in Cu caused by a confounding factor will then be readily 
apparent. To allow for changes in Cp caused by age, sex, or 
inflammation, authors have suggested routinely adjusting 
serum Cu for the Cp concentration98 or calculating the Cu:Cp 
ratio.99 Laboratories should determine their own adjustment 
equation or ratio because these depend on the methods used 
and population studied.100
Cuproproteins
Many cuproproteins other than Cp have been investigated as 
possible markers of Cu status, but none reliably detect early 
deficiency or toxicity.5,101 Assays are unstandardized, necessi-
tating that individual laboratories determine local reference 
ranges. These tests are also subject to high intraindividual vari-
ation. Lability of cuproenzymes may necessitate rapid speci-
men processing, confining analysis to hospitalized patients. 
There is also limited information available on the diagnostic 
sensitivity and specificity of these tests.
Superoxide dismutase in red blood cells is considered a 
relatively sensitive marker of Cu deficiency, decreasing in Cu 
deficiency and in subjects with low Cu intake, but the change 
occurs slowly because of slow turnover of red blood cells.102 
Plasma diamine oxidase decreases in Cu-deficient subjects but 
has limited use in diagnosis because it increases during tissue 
injury. Studies have also investigated platelet cytochrome C 
oxidase as a biomarker of Cu status, but it is limited by lability 
and high interindividual variation. Neither marker is routinely 
measured in clinical practice. These are discussed in detail 
elsewhere.4,89
Cu chaperone for superoxide dismutase (CCS) is the most 
promising potential biomarker of Cu status. In humans, mono-
nuclear cell mRNA for CCS increases in malnourished 
Cu-deficient patients and decreases in response to Cu supple-
mentation.102,103 A recent study observed that neither CCS pro-
tein nor mRNA transcripts were influenced by inflammatory 
status, supporting their use as biomarkers of Cu status.104
Liver Cu
The most reliable indicator of Cu status is liver Cu concentra-
tion, but this has limitations.97 First, underestimation may 
result from inhomogeneous distribution of Cu.105 Second, liver 
biopsy may be unsafe or contraindicated for some patients and 
is not feasible to repeat frequently, because of its invasive 
nature. A recently established technique called laser ablation–
inductively coupled plasma–mass spectrometry has been used 
to measure liver Cu concentrations.106 It is more accurate, 
quicker, and cheaper than standard metal deposit measurement 
and can simultaneously measure Zn and selenium. When 
applied to liver specimens from patients with WD, it has con-
firmed that hepatic Cu is inhomogeneously distributed, but the 
technique has not yet been applied to PNALD. The prognostic 
value of this method is worthy of assessment, but ideally, 
hepatic Cu would be measured noninvasively. This may even-
tually be possible through imaging techniques.101
Metabolomics and Transcriptomics
Clinically useful biomarkers of micronutrient status may be 
identified by using -omics techniques to detect changes in 
response to supplementation.107 As yet, few such approaches 
have been described in relation to Cu status. A recent study of 
proteins correlating with micronutrient status in undernutrition 
unexpectedly identified a Ras protein that explained variation 
in plasma Cu concentration additional to that explained by Cp. 
This protein merits further investigation as a biomarker of Cu 
status.108 A network of proteins representing the Cu interac-
tome identified ATPases 7A and 7B as proteins worthy of fur-
ther assessment as markers of Cu status.102
There is a clinical need for biomarkers, ideally measurable 
in peripheral blood, that can detect Cu accumulation before the 
onset of clinical features. Studies in animals have shown that 
-omics approaches can sensitively detect Cu toxicity by observ-
ing genetic and metabolic changes. A transcriptomics approach 
observed downregulation of genes associated with cholesterol 
synthesis, as in a mouse model of WD, and upregulation of 
metallothionein and catalase.109 A metabolomics approach 
identified a metabolic signature of Cu exposure.110 These tech-
niques have not yet been applied to the study of Cu exposure in 
humans. At present it is difficult to predict which patients are 
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susceptible to Cu accumulation, but the ability to do this could 
guide Cu provision. Gene testing may have predictive value 
because it is likely that genetic factors contribute to interindi-
vidual variation in the effects of Cu exposure. For example, 
individuals who are heterozygous for ATP7B mutations for 
WD may be predisposed to liver disease when exposed to 
excess Cu during long-term PN. The carrier frequency for 
these genes is relatively common at 1 in 90.111 These are all key 
areas for future research.
Practical Considerations
Standard Requirements
In 1979 the American Medical Association published recom-
mendations on Cu supplementation of PN based on knowledge 
of oral intake and estimated absorption of Cu from a normal 
diet.83 The amount recommended for adults was 0.5–1.5 mg/d. 
Subsequently, the results of Cu balance studies suggested that 
the dose should be lower.92 In response to this, the American 
Society for Parenteral and Enteral Nutrition (ASPEN) changed 
the standard recommendation to 0.3–0.5 mg/d, which has 
remained unchanged since 2002112 (Table 1). The European 
Society for Clinical Nutrition and Metabolism (ESPEN) made 
the same recommendation in its guidance on perioperative 
PN.114 These recommendations were supported by a recently 
published systematic review of TE supplementation in PN.115
Individualization of Cu Provision
Standard recommendations should be considered a starting 
point for estimating individual requirements and adjusting Cu 
provision accordingly. However, studies suggest that in prac-
tice this is poorly done. A 2013 Canadian review of 135 patients 
treated with long-term PN observed that Cu supplementation 
was 0.64 ± 0.35 mg/d, exceeding the standard recommenda-
tion.116 Supplementation did not appear to be influenced by 
factors such as the GI anatomy of individual patients or indica-
tion for PN. This failure to adjust Cu provision risks causing 
deficiency or toxicity. Similarly, a retrospective observational 
study of TE status and dosing among 26 adult patients treated 
with long-term PN reported that 95.5% of Cu doses delivered 
exceeded the standard recommendation.117 Cu doses of 1 mg/d 
resulted in hypercupremia in 22.5% of the tests performed. The 
excessive Cu dosing observed in these studies is in part a con-
sequence of inappropriately formulated MTE products.
In practice, prescribers have insufficient information to 
enable them to fully individualize Cu doses. This would require 
knowledge of the patient’s Cu status, the disease-specific 
requirements, and the amount of bioavailable Cu already pres-
ent in the PN and other sources. Nevertheless, individual clini-
cal circumstances should be carefully assessed and Cu provision 
adjusted if necessary. In what follows, situations are considered 
in which individual requirements may differ from the standard 
recommendation. The discussion is confined to Cu, but in prac-
tice all micronutrients should be considered together.
Increased requirements. Cu requirements increase for 
patients with prolonged, increased GI losses or persistent 
malabsorption.16,118 In this situation, it may be appropriate to 
give higher doses of Cu. Balance studies have suggested that 
patients with persistent diarrhea (GI secretions >300 g/d) 
require 0.4–0.5 mg/d to maintain balance (ie, doses at the 
upper end of the standard recommendation).92 This study 
investigated patients receiving total PN. In practice, however, 
many patients with short bowel take some oral diet, the effect 
of which on parenteral Cu requirement is difficult to predict. 
Oral diet resulting in net Cu absorption will decrease the 
requirement. However, oral diet also stimulates the produc-
tion of Cu-containing secretions, potentially resulting in net 
Cu loss and an increased requirement. In practice the net 
effect of oral diet on parenteral Cu requirement is unknown 
because it is not feasible to carry out balance studies with 
individual patients.
The observations of high exudative Cu losses for patients 
with severe burns suggest that Cu requirements are likely to 
increase in these patients. ASPEN has recommended higher Cu 
provision in this situation.73 ESPEN has recommended increas-
ing provision 5-fold (3.0–3.5 mg/d) especially while wounds 
remain open.119 Higher Cu doses may also be required to 
replace dialysate losses for patients treated with continuous 
renal replacement therapy.46 Increased Cu provision should 
also be considered for patients treated with cisplatin.48 Clearly, 
higher doses are required for patients with Cu deficiency. If 
deficiency is suspected, it may be appropriate to increase Cu 
supplementation to provide at least 1.0 mg/d in PN.16
Decreased requirements. Various publications suggest that for 
critically ill patients the amount of Cu that would be required in 
PN is decreased. ESPEN recommends that, except for patients 
with severe burns, parenteral Cu requirements are below the 
amount provided by currently available MTE products.119 Else-
where, authors have recommended against delivery of Cu to 
Table 1. Parenteral Copper Requirements in Adults.
Condition: 
Requirement, mg/d Year Reference
Stable  
 0.5–1.5 1979 83
 0.3–0.5 2002 112
 317–518a 2014 113
Diarrhea: 0.4–0.5 1981 92
Cholestasis: 0.15 1981 92
aValues in µg/d.
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critically ill patients at doses >1.2 mg/d.120 In a study of Cu 
provision for critically ill patients treated with PN, doses of 0.3 
mg/d were sufficient to maintain constant serum Cu concentra-
tions.121 In consideration of these recommendations, it should 
be remembered that critical illness encompasses a diverse range 
of conditions and disease severities.
It may be necessary to decrease Cu provision for patients 
with cholestasis. A difficulty in practice is that cholestasis is 
difficult to quantitate and its severity varies widely. Ideally, it 
would be quantitated by direct measurement of bile flow, but 
this cannot be done in clinical practice. Clinicians therefore 
have to rely on surrogate measures and the presence of clinical 
features. Cholestasis can be considered to be present if there is 
direct (conjugated) hyperbilirubinemia with (1) direct bilirubin 
>1 mg/dL when total bilirubin is <5 mg/dL or (2) direct biliru-
bin >20% of total bilirubin when it is >5 mg/dL.3
Limited data are available on which to base guidance on par-
enteral Cu provision for patients with cholestasis. However, the 
observations of liver Cu accumulation for patients with cholesta-
sis suggest that caution is necessary.81,82 Howard et al recom-
mended that Cu be withheld once liver aminotransferase and 
alkaline phosphatase levels increase to twice that of reference 
values and before serum bilirubin levels increase.82 ASPEN has 
recommended decreasing or withholding Cu provision for 
patients with significant cholestasis or liver disease.73 On the 
basis of balance studies, a dose of 0.15 mg/d has been sug-
gested.92 Doses below this, if continued indefinitely, risk the 
development of deficiency. This contention is supported by the 
reports of severe Cu deficiency occurring for patients with cho-
lestasis after Cu has been withheld from PN.21,22 The risk of defi-
ciency would be expected to be higher if GI losses increase or if 
there is high Zn provision. To avoid the development of Cu defi-
ciency for patients with cholestasis, it may be preferable to 
decrease Cu provision rather than to withhold it altogether. 
Whether decreased or withheld, Cu provision should be kept 
under close review because individual requirements may change.
Monitoring of Cu Status
Serum Cu should be measured regularly for patients treated 
with long-term PN and in any patient in whom Cu deficiency 
is suspected. There are limited data available to guide the fre-
quency of measurements, the recommendations being based on 
expert opinion. ESPEN guidelines on home PN recommend 
measuring serum Cu every 6 months.122 The frequency of mea-
surements should be increased for patients who are clinically 
unstable.123 A recent study of TE monitoring among critically 
ill patients observed that significant cost savings could be 
made by targeting the sickest patients for monitoring, as 
opposed to automatic testing of all patients.124 For patients 
with cholestasis supplemented with Cu provided by a standard 
MTE product, 6-monthly monitoring of Cu should suffice,16 
but 3-monthly monitoring has been recommended for patients 
with increased total bilirubin attributed to liver disease.125 For 
patients treated with PN from which supplemental Cu has been 
withheld, monthly monitoring has been recommended to facil-
itate early detection of Cu deficiency.16,125
Serum Cu results should be considered in the clinical con-
text and along with the results of other investigations. Factors 
to consider in the practical assessment of Cu status are sum-
marized in Table 2. Causes and features of Cu deficiency 
should be sought and C-reactive protein measured to assess the 
APR.113 If Cu deficiency is suspected, a full blood picture 
should be ordered, to exclude hematologic features of defi-
ciency, and a trial of supplementation considered.22,72 
Resolution of features in response to supplementation may 
help to confirm the diagnosis. Serum Zn should be measured 
during long-term PN to exclude Zn excess. Zn excess can also 
Table 2. Practical Assessment of Cu Status During Parenteral Nutrition.
Assessment Rationale
Clinical workup  
 History Elicit possible causes and consequences of Cu deficiency and toxicity.
 Examination Elicit anemia, poor wound healing, and neurologic abnormalities, which may occur in deficiency. Features 
of liver disease may occur in PNALD.
Biochemistry (serum)  
 Cu Hypocupremia is consistent with Cu deficiency.
 Cp Assists with interpretation of serum Cu results.
 CRP Assists with interpretation of serum Cu by quantifying APR.
 Zn Overprovision of enteral or oral Zn can cause Cu deficiency.
 Fe status Fe deficiency may coexist with Cu deficiency.
 Vitamin B
12
, D, E Vitamin deficiency may coexist with Cu deficiency.
Full blood picture Microcytic or normocytic anemia and neutropenia can occur in Cu deficiency.
Liver Cu Confirmation of Cu accumulation.
Bone imaging Osteoporosis can occur in Cu deficiency.
APR, acute phase response; Cp, ceruloplasmin; CRP, C-reactive protein; Cu, copper; Fe, iron; PNALD, parenteral nutrition–associated liver disease; Zn, 
zinc.
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be excluded by 24-hour urine Zn <19 µmol.40 Vitamin B
12
 sta-
tus should be assessed, especially after gastric surgery. Its defi-
ciency may coexist with that of Cu, as can deficiencies of Fe 
and vitamins D and E. If Cu accumulation is suspected, fea-
tures of cholestatic liver disease should be sought and liver 
function tests measured. Liver biopsy may be considered to 
measure the liver Cu concentration.
Cu Contamination
Contamination of PN with Cu may result in excessive delivery 
of Cu. One study that examined 8 component solutions 
observed that Cu was 1 of 12 TEs present in amounts >1 µg/L 
in every solution.126 Cu was a minor contaminant present in PN 
at a final concentration of 82 µg/2L. Cu was present as a con-
taminant in the amino acid solutions and sterile water but not 
in potassium chloride, sodium chloride, and calcium gluconate 
solutions. More recently, Cu was reported as a contaminant 
from 5 of 14 PN components undeclared on the product 
label.127 The actual amount of Cu was estimated to exceed the 
prescribed amount by 7%–426%. The total Cu contamination 
of a PN regimen depends on the volume of individual compo-
nents added and has been reported to range from 0.1–0.4 
mg/d.15 Patients treated with PN may receive Cu in other IV 
fluids, causing the total amount delivered to greatly exceed the 
amount prescribed. Contamination is highest in blood products 
such as packed red blood cells and frozen plasma and in albu-
min solutions (0.5 mg/L) and crystalloids (0.14 mg/L).128 
Berger and Cavadini estimated that critically ill patients, with 
burns or trauma who were treated with large volumes of these 
fluids, received Cu doses 2.3 times the RDA.128
The inadvertent delivery of Cu raises safety concerns. 
Whether safety is compromised depends on the individual clin-
ical circumstances and on the amount of Cu delivered. The 
concerns are greatest for patients with cholestasis who are 
treated with long-term PN. ASPEN has recommended that Cu 
contamination of composite PN regimens delivered to adults 
should not exceed 0.1 mg/d.73 To achieve this target, all com-
ponents of PN should be considered.
Stability Considerations
Unwanted interactions among components of PN can result in 
precipitation or degradation of micronutrients. Cu has been 
reported to interact with cysteine to form precipitates that are 
trapped by the filter, thereby decreasing the bioavailability of 
both nutrients. The mechanism of precipitation is uncertain, 
but spectroscopic examination of precipitates recently identi-
fied Cu and sulfur as the main elements.129 Cu may react 
directly with cysteine to form Cu cysteinate. Alternatively, it 
may react with hydrogen sulfide, formed from cysteine by 
heat sterilization, to form Cu sulfide.130 The probability of 
precipitation is highest at high concentrations of both nutri-
ents, the Cu concentration in one reported case being 170 
µg/L.131 It may also be influenced by the timing of additions. 
When cysteine was added to PN immediately before infusion, 
no significant differences were observed between prefilter and 
postfilter concentrations of Cu and cysteine, nor was there vis-
ible precipitation.132 The authors concluded that L-cysteine 
added to PN immediately before infusion is stable over 24 
hours of infusion. This interaction can be prevented by omis-
sion of Cu from PN, but this is impractical. Instead, limiting 
the Cu concentration to 157 µg/L with the use of low-pH cys-
teine-containing amino acid solutions has been suggested.133 
When Cu requirements are high, it may be necessary to deliver 
some or all of the Cu by a separate IV infusion. The feasibility 
of providing Cu enterally should also be considered.
Ascorbic acid is the biologically active form of vitamin C. 
It is an unstable component of PN, being reversibly oxidized 
anaerobically to dehydroascorbic acid that, in the presence of 
oxygen and Cu, is irreversibly oxidized to inactive diketogulo-
nic acid.134 This is then further oxidized to oxalate. The oxygen 
for this reaction reaches PN either in component solutions or 
by permeation through the wall of the bag. Ascorbate can be 
protected during storage of PN by using multilayered bags that 
are less permeable to oxygen.135,136 As new PN regimens are 
developed, the potential for interaction of components with Cu 
should be considered.
MTE Products
It is difficult for prescribers to comply with the current ASPEN 
recommendations on Cu provision in PN because of the formu-
lation of most MTE products currently available in the United 
States and Europe. These products provide up to twice the rec-
ommended amount of Cu, which exceeds most patients’ 
requirements, and a recent review concluded that they were 
potentially toxic.73 Moreover, the formulation of these prod-
ucts is not conducive to individualization of Cu dosing. When 
prescribers wish to decrease or withhold Cu, the MTE product 
must be withheld and the PN regimen supplemented individu-
ally with the necessary doses of Cu, selenium, and Zn. When 
Cu provision is being increased, it is not safe to increase the 
MTE dosage, because this could result in excessive provision 
of manganese and other TEs. In this situation, the PN regimen 
can be supplemented with an individual Cu product, unless sta-
bility considerations demand that the Cu be delivered by a 
separate IV infusion. These approaches are costly and labor 
intensive and increase the risk of errors.
ASPEN has made a call to action to bring safer products to 
the market, recommending that Cu doses provided by adult par-
enteral MTE products are decreased to 0.3–0.5 mg/d.137 
Similarly, the Australasian Society for Parenteral and Enteral 
Nutrition has recommended that Cu dosing in MTE products, 
for the Australian and New Zealand market, be decreased to 315 
µg/d.113 In addition, there may be a place for low-Cu MTE prod-
ucts for use among patients whose requirements are below the 
standard recommendations. Ideally, a range of products should 
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be developed with doses of Cu and other TEs appropriate for 
situations commonly encountered in practice. The availability of 
such products would greatly facilitate individualization of Cu 
provision. There is also a need for pharmaceutic companies to 
routinely provide information on Cu contamination—in PN 
products and other IV fluids as well. The availability of this 
information would inform decisions on supplementation.
ASPEN has provided guidance on managing product short-
ages,26,138 summarized briefly here. Most important, supplies 
should be reserved for the most vulnerable patients—namely, 
those with existing deficiency or at high risk of developing defi-
ciency if micronutrients are withheld. TEs should be supple-
mented orally for patients with sufficient GI absorptive capacity. 
Rationing may be necessary—for example, by delivering stan-
dard doses 3 times weekly rather than daily or by providing 
daily delivery of half the standard dose. If rationing is neces-
sary, clinicians should be alert to possible deficiencies and 
should monitor patients accordingly. Supplies should be sought 
for micronutrients, including Cu, for which deficiency is likely 
to occur if the micronutrient is withheld. Advice on strategic 
planning for future shortages is available elsewhere.139
Future Directions
Prescribers of micronutrients should aspire to individualize 
provision. However, much research and development will be 
necessary before true individualization of Cu provision is pos-
sible. More information is required on the Cu provision 
required to maintain optimal status in different diseases, espe-
cially critical illness. Sensitive and specific biomarkers of Cu 
status will need to be developed, enabling mild derangements 
in Cu status to be detected and provision to be adjusted before 
the onset of clinical features. It is likely that new tests will 
emerge from studies using -omics technologies or from stud-
ies of the effects of Cu deficiency on physiologic systems such 
as the immune system. The availability of better tests of Cu 
status will decrease the uncertainty that affects decisions on 
Cu provision in PN. It will also facilitate the study of marginal 
Cu deficiency in hospitalized patients and in the general popu-
lation. There is an urgent need for a range of appropriately 
formulated MTE products to be developed, both to enable 
compliance with the 2012 ASPEN recommendations and to 
facilitate adjustment of parenteral Cu doses.
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